AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15110741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 20
Study 12397861 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 24
Study 9565436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplements (100,000 IU for children ≤1 year and 200,000 IU for children >1 year on admission, followed by 50,000 IU and 100,000 IU respectively the next day)
Number of subjects: 95
Study 9565436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplements
Number of subjects: 95
Study 9565436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 7932681 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program (four nurse home visits during the first 6 months of life)
Number of subjects: 121
Study 7932681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 121
Study 3279698 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG RIVM (1 x 10(9) bacilli in 50 mL saline) administered once a week for six consecutive weeks
Number of subjects: 308
Study 3279698 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (30 mg in 50 mL saline) administered once a week for one month and thereafter once a month for a total of six months
Number of subjects: 308
Study 28485200 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid cardiothoracic ultrasound (CaTUS) protocol combining lung ultrasound (LUS) and focused echocardiographic evaluation of cardiac filling pressures
Number of subjects: 60
Study 28485200 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid cardiothoracic ultrasound (CaTUS) protocol
Number of subjects: 60
Study 28485200 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS response
Number of subjects: 60
Study 27659572 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheters
Number of subjects: 200
Study 27659572 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon catheters
Number of subjects: 200
Study 25291749 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal diffractive IOL AT LISA tri 839 MP
Number of subjects: 30
Study 25291749 — intervention group
Group type: COMPARATOR
Intervention: Bifocal diffractive IOL AT LISA 801
Number of subjects: 30
Study 24237191 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile, meadowsweet, and willow bark (CMW) in a berry extract matrix
Number of subjects: 20
Study 24237191 — intervention group
Group type: COMPARATOR
Intervention: Placebo (berry extract matrix)
Number of subjects: 20
Study 20876922 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term TENS therapy via L-S orthoses (3 times a day for 20 minutes)
Number of subjects: 39
Study 20876922 — intervention group
Group type: COMPARATOR
Intervention: Conventional TENS therapy (once a day for 20 minutes)
Number of subjects: 39
Study 18448861 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 384
Study 17160228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection using patent blue alone or in association with radiotracer based on technetium 99m colloid solution.
Number of subjects: 31
Study 17160228 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of transoperative lympho‐scintigraphy.
Number of subjects: 31
Study 17160228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node detection and analysis.
Number of subjects: 31
Study 14981970 — intervention group
Group type: EXPERIMENTAL
Intervention: sME treatment (therapy group)
Number of subjects: 689
Study 14981970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no complementary treatment)
Number of subjects: 689
Study 10744093 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline comparability presented in tables
Number of subjects: 50
Study 10744093 — intervention group
Group type: EXPERIMENTAL
Intervention: Significance tests for baseline comparison
Number of subjects: 50
Study 10744093 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods of randomisation
Number of subjects: 50
Study 10744093 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 50
Study 10744093 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted results
Number of subjects: 50
Study 10744093 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup findings
Number of subjects: 50
Study 10744093 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 50
Study 8792735 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA Modular femoral component (n=9)
Number of subjects: 29
Study 8792735 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the same prosthesis (n=9)
Number of subjects: 29
Study 8792735 — intervention group
Group type: EXPERIMENTAL
Intervention: Duracon femoral component (n=11)
Number of subjects: 29
Study 8792735 — intervention group
Group type: COMPARATOR
Intervention: All femoral components (PCA Modular, modified version, Duracon)
Number of subjects: 29
Study 8456467 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug therapy (low-dose cyclosporine, azathioprine, methylprednisolone)
Number of subjects: 128
Study 8456467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza plus CsA
Number of subjects: 128
Study 8456467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza plus MP
Number of subjects: 128
Study 8456467 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA plus MP
Number of subjects: 128
Study 3079888 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel, 2.5 mg daily for 1-3 months
Number of subjects: 14
Study 3079888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29301646 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 8404
Study 29301646 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 8404
Study 26966353 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized formulation of CTZ-loaded polymethacrylate microspheres (10 mg CTZ)
Number of subjects: 0
Study 26966353 — intervention group
Group type: COMPARATOR
Intervention: Commercial product of CTZ (marketed CTZ tablets)
Number of subjects: 0
Study 25011515 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative high-dose-rate intracavitary brachytherapy (2x8Gy)
Number of subjects: 185
Study 25011515 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (no preoperative treatment)
Number of subjects: 185
Study 23232585 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient fortified drink
Number of subjects: 246
Study 21978349 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner Asthma Communication and Education (PACE) Australia program
Number of subjects: 221
Study 18068940 — intervention group
Group type: EXPERIMENTAL
Intervention: PregXercise CD‐ROM
Number of subjects: 0
Study 18068940 — intervention group
Group type: COMPARATOR
Intervention: CD‐ROM with neutral content
Number of subjects: 0
Study 16688997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginaton (0.5 mg/kg) added to St. Thomas' cardioplegic perfusion
Number of subjects: 40
Study 16688997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Ginaton)
Number of subjects: 40
Study 12967065 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply‐White Whitening Gel (5.9% hydrogen peroxide)
Number of subjects: 22
Study 10741708 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Number of subjects: 10
Study 10741708 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 10
Study 10741708 — intervention group
Group type: COMPARATOR
Intervention: Electric pulses
Number of subjects: 10
Study 10741708 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 10
Study 8936392 — intervention group
Group type: EXPERIMENTAL
Intervention: Left movers
Number of subjects: 24
Study 8936392 — intervention group
Group type: COMPARATOR
Intervention: Right movers
Number of subjects: 24
Study 1303133 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 0
Study 2412032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.i.d. given orally for 4 days
Number of subjects: 7
Study 2412032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 7
Study 31376917 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on 18F-FDG-PET
Number of subjects: 123
Study 31376917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 index
Number of subjects: 123
Study 31376917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical signature and fusion signature
Number of subjects: 123
Study 29337653 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB+Routine
Number of subjects: 225
Study 29337653 — intervention group
Group type: COMPARATOR
Intervention: Routine
Number of subjects: 225
Study 26910293 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exercise with a therapeutic inflatable ball (SEIB)
Number of subjects: 40
Study 26910293 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) therapy
Number of subjects: 40
Study 23983091 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (3 times a week for 12 weeks)
Number of subjects: 27
Study 23983091 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (normal activity)
Number of subjects: 27
Study 22568406 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental vaginal delivery due to fetal distress
Number of subjects: 5667
Study 22568406 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section due to fetal distress
Number of subjects: 5667
Study 22568406 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental vaginal delivery due to failure to progress
Number of subjects: 5667
Study 22568406 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section due to failure to progress
Number of subjects: 5667
Study 20533625 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step All Bond SE protocol (SE-1)
Number of subjects: 33
Study 20533625 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step All Bond SE protocol (SE-2)
Number of subjects: 33
Study 17611095 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax
Number of subjects: 14000000
Study 17611095 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 14000000
Study 16163148 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusch hygroscopic HME
Number of subjects: 20
Study 16163148 — intervention group
Group type: COMPARATOR
Intervention: Mediflux hygroscopic HME
Number of subjects: 20
Study 11791082 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)/NETA (Activella)
Number of subjects: 438
Study 11791082 — intervention group
Group type: COMPARATOR
Intervention: CEE/MPA (Prempro)
Number of subjects: 438
Study 10506679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg daily
Number of subjects: 100
Study 10506679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7611241 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg) on low salt diet (50 mmol Na/d)
Number of subjects: 3
Study 7611241 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg) on high salt diet (200 mmol Na/d)
Number of subjects: 3
Study 7611241 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (50 mg) on moderate salt diet (100 mmol Na/d)
Number of subjects: 3
Study 1609377 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (3 mg twice daily)
Number of subjects: 32
Study 1609377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6469428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of 50 mg atenolol and 12.5 mg chlorthalidone (Tenoretic Mite)
Number of subjects: 37
Study 6469428 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone alone
Number of subjects: 37
Study 31262768 — intervention group
Group type: COMPARATOR
Intervention: Single oral doses of TBPM-PI-HBr at 100 mg to 900 mg
Number of subjects: 124
Study 31262768 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of TBPM-PI-HBr at 300 mg or 600 mg every 8 hours
Number of subjects: 124
Study 31262768 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of TBPM-PI-HBr at 600 mg q8h
Number of subjects: 124
Study 31262768 — intervention group
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Number of subjects: 124
Study 29847330 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash grant
Number of subjects: 2170
Study 29847330 — intervention group
Group type: COMPARATOR
Intervention: Mental planning
Number of subjects: 2170
Study 26948785 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-animated video group
Number of subjects: 123
Study 26948785 — intervention group
Group type: COMPARATOR
Intervention: Standard-only group
Number of subjects: 123
Study 25135728 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective esophagogastric devascularization (sEGDV)
Number of subjects: 180
Study 25135728 — intervention group
Group type: COMPARATOR
Intervention: Non-selective esophagogastric devascularization (n-sEGDV)
Number of subjects: 180
Study 21942926 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 21 min
Number of subjects: 20
Study 21942926 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive interactive neurostimulation (InterX(®)) for 21 min
Number of subjects: 20
Study 20724402 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400 mg/day)
Number of subjects: 178
Study 20724402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 20724402 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 178
Study 17650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic group psychotherapy (S)
Number of subjects: 151
Study 17650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic group psychotherapy (A)
Number of subjects: 151
Study 16234046 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (.02 mg/kg)
Number of subjects: 40
Study 16234046 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1 or 3 mg/kg)
Number of subjects: 40
Study 16234046 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 40
Study 12148111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabag (UB)
Number of subjects: 110
Study 12148111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay-Safe (SS)
Number of subjects: 110
Study 10425980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine (30 mg)
Number of subjects: 30
Study 10425980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (100 mg)
Number of subjects: 30
Study 10425980 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 8529087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet and intensive physical exercise
Number of subjects: 18
Study 8529087 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study 2075382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole-citrate (500 mg) given daily for 14 days
Number of subjects: 20
Study 2075382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole-citrate (500 mg) given twice daily for 14 days
Number of subjects: 20
Study 2075382 — intervention group
Group type: COMPARATOR
Intervention: Levamisole 150 mg (two priming doses)
Number of subjects: 20
Study 6753559 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone (200 mg 4 times daily)
Number of subjects: 41
Study 6753559 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 41
Study 6753559 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 31534549 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 specific inhibitor Rofecoxib
Number of subjects: 42
Study 31534549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined COX-2 and DNMT inhibition using Celecoxib and Decitabine
Number of subjects: 42
Study 31534549 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 treatment
Number of subjects: 42
Study 29105115 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (6 g/day)
Number of subjects: 22
Study 29105115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 27348000 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4 mg∙kg(‐1)
Number of subjects: 11
Study 27348000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 27348000 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 11
Study 24163058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve block
Number of subjects: 100
Study 24163058 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study 22262013 — intervention group
Group type: EXPERIMENTAL
Intervention: Typing and mousing tasks for 60 min at a standardized workstation
Number of subjects: 20
Study 22262013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trapezius myalgia)
Number of subjects: 20
Study 19278329 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive laser-guided preincision localization device
Number of subjects: 76
Study 19278329 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's initial estimate of the target site
Number of subjects: 76
Study 17785765 — intervention group
Group type: EXPERIMENTAL
Intervention: IRINOX (irinotecan + oxaliplatin)
Number of subjects: 80
Study 17785765 — intervention group
Group type: COMPARATOR
Intervention: LV5 FU2 + oxaliplatin
Number of subjects: 80
Study 17785765 — intervention group
Group type: COMPARATOR
Intervention: LV5 FU2 + irinotecan
Number of subjects: 80
Study 14716219 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg)
Number of subjects: 21
Study 14716219 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (SR 160 mg)
Number of subjects: 21
Study 14716219 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 21
Study 11669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine at 37 degrees C
Number of subjects: 18
Study 11669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin at 37 degrees C
Number of subjects: 18
Study 11669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and Serotonin at 31 degrees C
Number of subjects: 18
Study 11669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (1-100 microM)
Number of subjects: 18
Study 11669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling from 37 to 31 degrees C
Number of subjects: 18
Study 11669167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium orthovanadate (10 microM)
Number of subjects: 18
Study 9677460 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + IFN-alpha (Arm A)
Number of subjects: 38
Study 9677460 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + 4-Epirubicin (Arm B)
Number of subjects: 38
Study 7990325 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex pathogenetic approach including wide operative access, one-stage cleansing with antiseptics and detoxification solutions, ultrasonic cavitation, creation of laparostomy, local infiltration with 0.01% thymalin solution, correction of hemostasis disorders, increase of general reactivity
Number of subjects: 21
Study 7990325 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 2658582 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 202
Study 2658582 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 202
Study 30889607 — intervention group
Group type: EXPERIMENTAL
Intervention: Xyloglucan + gelose
Number of subjects: 40
Study 30889607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28222558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb® (HAL®) gait training
Number of subjects: 24
Study 28222558 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (CGT)
Number of subjects: 24
Study 25490615 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (DL) with in-person supervision
Number of subjects: 48
Study 25490615 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL) with telepresent supervision
Number of subjects: 48
Study 25490615 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL) with in-person supervision
Number of subjects: 48
Study 25490615 — intervention group
Group type: COMPARATOR
Intervention: Videolaryngoscopy (VL) with telepresent supervision
Number of subjects: 48
Study 23356523 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat activation methods (implicit to explicit)
Number of subjects: 931
Study 21355982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberwand
Number of subjects: 57
Study 21355982 — intervention group
Group type: COMPARATOR
Intervention: LUS‐II
Number of subjects: 57
Study 18654081 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 81
Study 18654081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 81
Study 16368878 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) combined with effective antiretroviral therapy (ART)
Number of subjects: 0
Study 16368878 — intervention group
Group type: COMPARATOR
Intervention: Effective antiretroviral therapy (ART)
Number of subjects: 0
Study 15648508 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated exertion of force test
Number of subjects: 60
Study 15648508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit‐rotor test
Number of subjects: 60
Study 15648508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegboard test
Number of subjects: 60
Study 11057441 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine
Number of subjects: 52
Study 11057441 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 52
Study 9279183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of recombinant hepatitis B vaccine at months 0, 1, 6 or 0, 1, 2, 12, with or without immunoglobulin at birth
Number of subjects: 167